Implantica announces successful completion of first RefluxStop® procedures in the U.S.
Implantica announces successful completion of first RefluxStop® procedures in the U.S. |
| [05-November-2026] |
VADUZ, Liechtenstein, Nov. 5, 2026 /PRNewswire/ -- Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including the innovative RefluxStop® device for the treatment of acid reflux, announces that the first RefluxStop® procedures in the U.S. were successfully performed yesterday at the University of Southern California (USC) in Los Angeles by leading U.S. anti-reflux surgeon, Dr. John Lipham, Chief of the Division of Upper GI and General Surgery, Keck School of Medicine of USC and Past President and Co-founder of the American Foregut Society. The first commercial RefluxStop® procedures in the U.S. mark a major milestone. RefluxStop® is designed to address the root cause of gastroesophageal reflux disease (GERD) by restoring the body's natural anti-reflux barrier, a fundamentally different approach to existing treatments of GERD. Dr. John C. Lipham said, "Performing the first RefluxStop® procedures in the U.S. marks an important milestone for our patients and our program. The patients are doing well, and I look forward to offering this innovative treatment to many more patients. Reflux is a mechanical problem, and it deserves to be resolved surgically by addressing its underlying anatomical cause. Traditional interventions primarily focus on reinforcing the lower esophageal sphincter (LES) often resulting in side effects such as swallowing difficulties and has contributed to the reduction of surgical treatment overall. In contrast, RefluxStop® features a unique mechanism of action that restores the natural anti-reflux barrier and as the long-term European clinical data have demonstrated, provides effective reflux control with much fewer side-effects." Dr. Lipham continued, "With RefluxStop we now have a solution that addresses a significant unmet medical need - not only for the approximately 40% of GERD patients who respond inadequately to medication1, but also for the more than one-third of sufferers with swallowing difficulties who have no well working treatment today. For decades, we have sought a treatment that provides effective reflux control without compromising patient's natural swallowing. Medication focuses only on GERD symptoms by reducing acid production and has been shown to potentially cause serious long-term side effects. With this advancement, we finally have an option that treats the disease at its root anatomical cause without compromising esophageal function." Dr. Peter Forsell, Inventor of RefluxStop, Founder, and CEO of Implantica, said, "Congratulations to Dr. Lipham and his world-class team at USC on completing the first RefluxStop® procedures in the U.S. It was an honor to observe the procedures and represents a defining landmark moment for the U.S. market and Implantica, but most importantly for the many millions of American GERD patients." Dr. Forsell continues, "We are very encouraged to see the strong interest in RefluxStop® among U.S. surgeons, GIs, and patients, and will continue to build the U.S. launch deliberately, center by center, with highest-quality surgeon training and ensuring excellent patient outcomes at the core. These chronic sufferers finally have an effective surgical alternative with limited side effects, as confirmed by the today 39 published articles on RefluxStop®, and we couldn't be more excited to bring our new treatment to the patients, a disease that affects 78 million Americans."
For further information, please contact: Implantica is listed on Nasdaq First North Premier Growth Market in Stockholm. The company's Certified Adviser is FNCA Sweden AB, info@fnca.se The information was sent for publication, through the agency of the contact person set out above, on November 5, 2026, at 08:00 a.m. (CET). About Implantica In addition to RefluxStop®, Implantica has developed a broad, patent-protected product pipeline partly incorporating two platform technologies: an eHealth platform designed to enable communication with and remote monitoring and control of implants inside the body, and a wireless energizing platform designed to wirelessly power implantable devices through intact skin. These investigational devices are intended to facilitate remote changes to treatment, potentially saving cost for society. Implantica is listed on Nasdaq First North Premier Growth Market (ticker: IMP A SDB). Visit www.implantica.com for further information. About RefluxStop® Indications for Use: RefluxStop® is an implantable sterile medical device intended to treat acid and non-acid reflux in patients diagnosed with gastroesophageal reflux disease (GERD). The device ensures maintenance of a normal physiological situation for the gastroesophageal junction (GEJ) in a defined intra-abdominal position, allowing natural physiological function of the lower esophageal sphincter (LES), thereby reducing or eliminating acid and non-acid reflux. The RefluxStop® Deployment Tool is indicated for patients diagnosed with Gastroesophageal Reflux Disease (GERD), defined by abnormal impedance pH and/or pH testing, and indicated for RefluxStop® implantation. Newsroom Community Media Contact: This information was brought to you by Cision http://news.cision.com The following files are available for download:
SOURCE Implantica | ||||||||||
Company Codes: ISIN:SE0014855029,Stockholm:IMP-A-SDB |
View original content:
